FDA approves Invokamet from Janssen Pharmaceuticals

RARITAN, N.J. — Janssen Pharmaceuticals received approval from the Food and Drug Administration for Invokamet, a fixed-dose therapy that combines canagliflozin and metformin hydrochloride in a single tablet. The drug is used for the treatment of adults with Type 2 diabetes.

“Invokamet combines, in one tablet, two complementary therapeutic approaches proven effective for managing Type 2 diabetes,” said Richard Aguilar, M.D. and medical director of Diabetes Nation. “Canagliflozin works with the kidney to promote the loss of glucose in the urine, whereas metformin decreases the production of glucose in the liver and improves the body's response to insulin.”

Invokamet will be available in tablets containing canagliflozin 50 mg or 150 mg, and metformin 500 mg or 1000 mg, the company stated. The recommended dosing is twice daily.

Login or Register to post a comment.